AN-1155

HPLC as a Complimentary Technique to Quantify Bevacizumab

Cristina Pangua¹, Socorro Espuelas, PhD¹, Juan M. Irache, PhD¹, Mandana Fasth², Iñaki Gorostiza², and Bryan Tackett, PhD³

¹University of Navarra, Department of Chemistry and Pharmaceutical Technology, C/Irunlarrea, 1, Pamplona 31008, Navarra, Spain ²Phenomenex Spain, C/Valgrande, 8, Edificio Thanworth II Planta 2.1.B, 28108 Alcobendas, Spain ³Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501 USA

Overview

Bevacizumab is a monoclonal antibody used as an immunotherapy for several types of cancers. One common technique to quantify monoclonal antibodies (mAb) is the use of Enzyme-Linked Immunosorbent Assay (ELISA). ELISA offers some advantages, including a high selectivity and sensitivity and the possibility to perform analysis without complicated sample pre-treatment. However, it is very labor intensive and its elevated cost and relatively short expiration date due to antibody instability limits its use in routine analytical quantification. There is also a high potential for false positive/negative results which leads to variability and low confidence in those results. In many instances there is inadequate inhibition of immunogenic antigens due to cross reactivity, leading to weak (or low) signal intensity.

High-performance Liquid Chromatography (HPLC) alleviates many of the common challenges associated with ELISA. It is a simpler technique that typically has a shorter total time for analysis. Compared to ELISA, HPLC is low-cost, more reproducible, and more sensitive, providing more reliable results. As such, HPLC is a more suitable tool in discovery, development, and manufacturing environments.

Employing an HPLC method allowed us to evaluate the capability of albumin-based nanoparticles to encapsulate Bevacizumab, to study its release from these nanoparticles in simulated physiological media and show adequate separation between peaks from Human Serum Albumin (HSA) (65 kDa) and Bevacizumab (150 kDa). In this application note, we provide a simple, rapid, and low-cost method for the quantification of Bevacizumab formulated in HSA-based nanoparticles using a Biozen 3 μ m dSEC-2 HPLC Column. The bioinert hardware and hydrophilic surface chemistry of the Biozen dSEC-2 column offers sufficient resolution to reliably separate and quantify both Bevacizumab and HSA reproducibly.

LC Conditions

Columns:Biozen™ 3 μm dSEC-2Dimensions:300 x 4.6 mmPart No.:00H-4788-E0Mobile Phase:35 mM Phosphate Buffer + 300 mM
NaCl, pH 6.8Flow Rate:0.2 mL/min (Isocratic)Injection Volume:10 μLTemperature:25 °CDetector:PDA @ 280 nmLC System:Agilent® 1200 Series




Figure 1. 200 µg/mL HSA in an Aqueous Solution on Biozen[™] 3 µm dSEC-2 Column.







Figure 3. 200 $\mu g/mL$ HSA and 200 $\mu g/mL$ Bevacizumab in an Aqueous Solution on Biozen 3 μm dSEC-2 Column.




No.	Analyte	(min)	wiath	Area	Height
1	Bevacizumab	14.504	0.329	704.86	32.83
2	Human Serum Albumin	15.445	0.279	199.00	11.01

Biozen 3 µm dSEC-2 Column.







Peak No.	Analyte	Retention Time (min)	Width	Area	Height
1	Bevacizumab	14.045	0.384	805.76	30.49
2	Human Serum Albumin	15.387	0.288	3113.16	163.40

Table 1. Comparison Between the Quantification of Bevacizumab by ELISA versus HPLC.

	ELISA	HPLC	
Lowest limit of quantification	30 ng/mL	12.5 μg/mL	
Total time for analysis (min)	70	17	
Sample numbers	96	Depends on the lifetime of the column (~1000 injections)	
Bevacizumab loading (µg Bevacizumab/mg formulation)*	26 ± 4	28 ± 2	

*Data expressed as Mean \pm SD, n=10.



Figure 2. 200 μg/mL Bevacizumab in an Aqueous Solution on Biozen 3 μm dSEC-2 Column.

Need a different column size or sample preparation format?

No problem! We have a majority of our available dimensions up on <u>www.phenomenex.com</u>, but if you can't find what you need right away, our super helpful Technical Specialists can guide you to the solution via our online chat portal <u>www.phenomenex.com/Chat</u>.

India

Indonesia

Ireland

Japan t: +81 (0) 120-149-262

Mexico

t: +62 21 5019 9707

t: +353 (0)1 247 5405

Italy t: +39 051 6327511

Luxembourg t: +31 (0)30-2418700

t: 01-800-844-5226

The Netherlands

t: +31 (0)30-2418700

New Zealand

Norway t: +47 810 02 005

t: +48 22 104 21 72

Poland

t: +64 (0)9-4780951

nlinfo@phenomenex.com

nzinfo@phenomenex.com

nordicinfo@phenomenex.com

pl-info@phenomenex.com

t: +91 (0)40-3012 2400

indiainfo@phenomenex.com

indoinfo@phenomenex.com

eireinfo@phenomenex.com

italiainfo@phenomenex.com

jpinfo@phenomenex.com

nlinfo@phenomenex.com

tecnicomx@phenomenex.com

Australia t: +61 (0)2-9428-6444 auinfo@phenomenex.com

Austria t: +43 (0)1-319-1301 anfrage@phenomenex.com

Belgium t: +32 (0)2 503 4015 (French) t: +32 (0)2 511 8666 (Dutch) beinfo@phenomenex.com

Canada t: +1 (800) 543-3681 info@phenomenex.com

China t: +86 400-606-8099 cninfo@phenomenex.com

Czech Republic t: +420 272 017 077 cz-info@phenomenex.com

Denmark t: +45 4824 8048 nordicinfo@phenomenex.com

Finland t: +358 (0)9 4789 0063 nordicinfo@phenomenex.com

France t: +33 (0)1 30 09 21 10 franceinfo@phenomenex.com

Germany t: +49 (0)6021-58830-0 anfrage@phenomenex.com

Hong Kong t: +852 6012 8162 hkinfo@phenomenex.com

www.phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country/region, contact Phenomenex USA, International Department at international@phenomenex.com



Your happiness is our mission. Take 45 days to try our products. If you are not happy, we'll make it right. www.phenomenex.com/behappy

Portugal t: +351 221 450 488 ptinfo@phenomenex.com

> Singapore t: +65 6559 4364 sginfo@phenomenex.com

Slovakia t: +420 272 017 077 sk-info@phenomenex.com

Spain t: +34 91-413-8613 espinfo@phenomenex.com

Sweden t: +46 (0)8 611 6950 nordicinfo@phenomenex.com

Switzerland t: +41 (0)61 692 20 20 swissinfo@phenomenex.com

Taiwan t: +886 (0) 0801-49-1246 twinfo@phenomenex.com

Thailand t: +66 (0) 2 566 0287 thaiinfo@phenomenex.com

United Kingdom t: +44 (0)1625-501367 ukinfo@phenomenex.com

USA t: +1 (310) 212-0555 www.phenomenex.com/chat

 All other countries/regions Corporate Office USA
 t: +1 (310) 212-0555
 www.phenomenex.com/chat

Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at <u>www.phenomenex.com/phx-terms-and-conditions-of-sale</u>. Trademarks

Biozen and BE-HAPPY are trademarks of Phenomenex. Agilent is a registered trademark of Agilent Technologies, Inc.

Disclaimer

Comparative separations may not be representative of all applications. Phenomenex is in no way affiliated with Agilent Technologies, Inc.

FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures. © 2023 Phenomenex, Inc. All rights reserved.

